THE PRELIMINARY CLINICAL-EVALUATION OF THE SAFETY AND EFFICACY OF A FERTILITY REGULATING VACCINE

被引：8

作者：

GRIFFIN, PD

JONES, WR

机构：

[1] World Health Organization, Geneva

[2] Department of Obstertrics and Gynaecology, Flinders Medical Centre, Bedford Park, South Australia

来源：

STATISTICS IN MEDICINE | 1991年 / 10卷 / 02期

关键词：

BIRTH CONTROL VACCINE; HUMAN CHORIONIC GONADOTROPIN (HCG); IMMUNOSAFETY;

D O I：

10.1002/sim.4780100204

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Since the mid 1970s, the World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction, through its Task Force on Vaccines for Fertility Regulation, has been supporting and coordinating the development of a birth control vaccine based on a synthetic peptide representing part of the beta subunit of human chorionic gonadotrophin (beta-hCG). The majority of this work has been carried out in the laboratories of Dr V.C. Stevens at Ohio State University. This hCG vaccine has recently been tested for tolerability and immunogenicity in a phase I clinical trial, and a preliminary evaluation of the vaccine's efficacy in fertile women volunteers is currently being planned. This paper describes the preclinical and clinical testing of this vaccine and the problems and challenges presented by this novel preparation. These have included the need to carry out safety and efficacy studies in the baboon, and the difficulties of designing appropriate preclinical toxicity and immunosafety studies and clinical trial protocols in the absence of previous experience with vaccines of this type.

引用

页码：177 / 190

页数：14

共 10 条

[1]

Griffin P.D., A fertility regulating vaccine based on the carboxyl‐terminal peptide of human chorionic gonadotrophin, Immunological Approaches to Contraception and Promotion of Fertility, pp. 43-59, (1986)

[2]

Evaluating the safety and efficacy of placental antigen vaccines for fertility regulation, Clinical and Experimental Immunology, 33, pp. 360-375, (1978)

[3]

Chen H.C., Hodgen G.D., Primate chorionic gonadotrophins. Antigenic similarities to the unique carboxyl terminal peptide of hCG beta subunit, Journal of Clinical Endocrinology and Metabolism, 43, pp. 1414-1417, (1977)

[4]

Stevens V.C., Jones W.R., Preclinical safety studies on a hCG vaccine, Reproductive Immunology 1983, pp. 233-237, (1983)

[5]

Stevens V.C., Fertility control through active immunization using placental proteins, Immunological Approaches to Fertility Control, pp. 357-375, (1974)

[6]

Stevens V.C., Powell J.E., Lee A.C., Griffin P.D., Antifertility effects from immunization of female baboons with C‐terminal peptides of hCG beta subunit, Fertility and Sterility, 36, pp. 98-105, (1981)

[7]

Hingorani V., Kumar S., Anti‐hCG immunization‐Phase I clinical trials, Recent Advances in Reproduction and Regulation of Fertility, pp. 467-471, (1979)

[8]

Nash H., Talwar G.P., Segal S., Luukainen T., Johansson E.B., Vasquez J., Coutinho E., Sundaram K., Observations on the antigenicity and clinical effects of a candidate antipregnancy vaccine: β‐subunit of human chorionic gonadotrophin linked to tetanus toxoid, Fertility and Sterility, 34, pp. 328-335, (1980)

[9]

Shahani S.M., Kulkarni P.P., Patel K.L., Evaluation of immunological and safety data in women treated with Pr‐β‐hCG‐TT, Recent Advances in Reproduction and Regulation of Fertility, pp. 473-476, (1979)

[10]

Jones W.R., Bradley J., Judd S.J., Denholm E.H., Ing R.M.Y., Mueller U.W., Powell J.E., Griffin P.D., Stevens V.C., pp. 1295-1298, (1988)

← 1 →